Early clinical outcomes as a function of use of newer oral P2Y12 inhibitors versus clopidogrel in the EUROMAX trial.
about
Early clinical outcomes as a function of use of newer oral P2Y12 inhibitors versus clopidogrel in the EUROMAX trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Early clinical outcomes as a f ...... pidogrel in the EUROMAX trial.
@en
Early clinical outcomes as a f ...... pidogrel in the EUROMAX trial.
@nl
type
label
Early clinical outcomes as a f ...... pidogrel in the EUROMAX trial.
@en
Early clinical outcomes as a f ...... pidogrel in the EUROMAX trial.
@nl
prefLabel
Early clinical outcomes as a f ...... pidogrel in the EUROMAX trial.
@en
Early clinical outcomes as a f ...... pidogrel in the EUROMAX trial.
@nl
P2093
P2860
P1433
P1476
Early clinical outcomes as a f ...... opidogrel in the EUROMAX trial
@en
P2093
Arnoud van 't Hof
Debra Bernstein
Efthymios N Deliargyris
Freek W A Verheugt
Frédéric Lapostolle
Giovanni Gordini
Gregory Ducrocq
Jacob Steinmetz
Jayne Prats
Jennifer Adgey
P2860
P304
P356
10.1136/OPENHRT-2017-000677
P577
2017-11-28T00:00:00Z